Treatment of obesity and type 2 diabetes with insulin-sensitizers such as TZDs has become a major challenge in clinical practice because of their side effects that include weight gain, cardiovascular complications, and increased risk of fractures [43]. The gene discussed is INS; the disease is Obesity.